Ardelyx Inc ARDX:NASDAQ

Last Price$1.52NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.60 (68)
Ask (Size)$1.61 (169)
Day Low / HighN/A - N/A
Volume146.6 M
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Ardelyx Inc ( NASDAQ )

Price: $1.52
Change: -0.18 (10.59%)
Volume: 146.6 M
4:00PM ET 12/03/2021
 
 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $1.76
Change: -0.08 (4.35%)
Volume: 1.0 M
4:00PM ET 12/03/2021
 
 

Larimar Therapeutics Inc ( NASDAQ )

Price: $9.59
Change: +0.01 (0.10%)
Volume: 76.7 K
4:00PM ET 12/03/2021
 
 

Seelos Therapeutics Inc ( NASDAQ )

Price: $1.64
Change: -0.10 (5.75%)
Volume: 5.5 M
4:00PM ET 12/03/2021
 
 

AquaBounty Technologies Inc ( NASDAQ )

Price: $2.36
Change: -0.21 (8.17%)
Volume: 1.2 M
4:00PM ET 12/03/2021
 

Read more news Recent News

--Wedbush Adjusts Ardelyx PT to $2 From $1, Maintains Neutral Rating
12:32PM ET 11/30/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Ardelyx to Launch Drug for Irritable Bowel Syndrome in Q2 2022
10:28AM ET 11/30/2021 MT Newswires

Ardelyx (ARDX) said Tuesday it is planning to launch Isbrela, an approved treatment for irritable bowel syndrome with constipation in adults, in Q2 2022....

-- Earnings Flash (ARDX) ARDELYX Posts Q3 Loss $-0.42
8:01AM ET 11/12/2021 MT Newswires

...

-- Earnings Flash (ARDX) ARDELYX Posts Q3 Revenue $1.2M
8:01AM ET 11/12/2021 MT Newswires

...

View all Commentary and Analysis

Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors
2:27AM ET 10/25/2021 Seeking Alpha

Ardelyx: Is There Any Value Left After The Unexpected CRL?
11:02AM ET 8/02/2021 Seeking Alpha

Ardelyx: Second Opportunity
8:00AM ET 5/19/2021 Seeking Alpha

Ardelyx (ARDX) Investor Presentation - Slideshow
4:31AM ET 2/28/2021 Seeking Alpha

Company Profile

Business DescriptionArdelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA. View company web site for more details
Address34175 Ardenwood Boulevard
Fremont, California 94555
Phone+1.510.745.1700
Number of Employees86
Recent SEC Filing11/30/20218-K
President, Chief Executive Officer & DirectorMike Raab
Chief Financial & Accounting OfficerJustin A. Renz
Chief Scientific OfficerJeffrey W. Jacobs
Secretary, Chief Legal & Administrative OfficerElizabeth Grammer

Company Highlights

Price Open$1.71
Previous Close$1.70
52 Week Range$0.82 - 9.23
Market Capitalization$171.4 M
Shares Outstanding112.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/14/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.53
Beta vs. S&P 500N/A
Revenue$2.6 M
Net Profit Margin-1,386.48%
Return on Equity-132.31%

Analyst Ratings as of 11/30/2021

Buy
3
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset